AUS
NZ
UK
CA
USA
IND
Headlines
- Assenagon Asset Management S.A. reduced its stake in Pacific Biosciences of California, Inc. by 24.4% during the fourth quarter.
- Several institutional investors, including FMR LLC and State Street Corp, have adjusted their positions in the company, reflecting varied investment strategies.
- Mixed analyst ratings have been reported
Recently, there have been notable shifts in investment strategies concerning Pacific Biosciences of California, Inc. (NASDAQ:PACB). Assenagon Asset Management S.A. significantly reduced its stake by 24.4% in the fourth quarter, selling 68,796 shares and leaving a holding of 213,091 shares, with an approximate value of $390,000, as noted in filings with the Securities & Exchange Commission.
Meanwhile, other institutional investors have made substantial changes to their holdings. FMR LLC exhibited a considerable increase of 641.3% in its stake during the third quarter, now owning 408,151 shares valued at $694,000. Similarly, State Street Corp expanded its position by 5.7%, acquiring an additional 340,766 shares, thus holding a total of 6,276,156 shares worth $10,669,000. Notably, Soros Fund Management LLC increased its holdings by 23.6%, acquiring 400,000 more shares to total at 2,098,000 shares, valued at $3,567,000 during the same period. Further, Barclays PLC augmented its stake by 143%, reflecting a strategic investment move during the third quarter.
Insider Transactions and Stock Performance
The insider trading activities reflect strategic financial decisions within Pacific Biosciences of California. A notable transaction involved insider Oene Mark Van selling 34,405 shares, valued at approximately $69,842 on January 10th. This sale represented a 2.11% reduction in his holdings, which are now valued at $3,242,831.62. The transaction details are accessible through documents filed with the SEC.
In terms of market performance, shares of NASDAQ PACB opened at $1.69 on a recent Friday, marking a 2.4% increase. The stock's 52-week range has been between $1.16 and $7.50, highlighting considerable fluctuations. The company's financial ratios reveal a debt-to-equity ratio of 1.97, and both quick and current ratios are well above average, indicating substantial liquidity.
Company Profile
Pacific Biosciences of California, Inc. is engaged in developing and manufacturing advanced sequencing solutions aimed at addressing genetically complex challenges. The company’s offerings include systems based on single molecule real-time (SMRT) technology and various reagent kits to facilitate specific molecular biology workflows.
Institutional interest, alongside insider trading activities, remains a focal point for stakeholders and investors, offering insights into the strategic maneuvers within the organization.
